Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 11/20 | 0.47 |
| ▸ | PARG | Q86W56 | 6/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15168798 | 0.82 | PARG (0.42) | GRM2PARGGRIN1GRIN2BLMNA | |
| SCHEMBL1503038 | 0.81 | GRM2 (0.61) | GRM2PARGLMNAMAPT | |
| SCHEMBL1502926 | 0.80 | GRM2 (0.64) | GRM2PARGLMNAMAPT | |
| SCHEMBL1502974 | 0.80 | GRM2 (0.64) | GRM2PARGLMNAMAPT | |
| SCHEMBL1502968 | 0.80 | GRM2 (0.64) | GRM2PARGLMNAMAPT | |
| SCHEMBL6891162 | 0.78 | GRM2 (0.50) | GRM2PARG | |
| SCHEMBL15168876 | 0.78 | PARG (0.39) | GRM2PARGLMNAMAPT | |
| SCHEMBL1503233 | 0.77 | GRM2 (0.46) | GRM2PARGGRIN1GRIN2BMAPT | |
| SCHEMBL15168315 | 0.77 | GRM2 (0.50) | GRM2PARGGRIN1GRIN2B | |
| SCHEMBL6891306 | 0.76 | GRM2 (0.52) | GRM2PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721029-B1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2721029-B1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9315518-B2 | Imidazopyridin-2-one derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315518-B2 | Imidazopyridin-2-one derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315518-B2 | Imidazopyridin-2-one derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8765784-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765784-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765784-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130210768-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210768-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210768-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012174199-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2011034741-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210768-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | GRM2, GRM1, GRIA2 | GRM2 1/4885PARG 4644/4885METAP2 2729/4885 |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | GRM2, GRIN2C, GRM1 | GRM2 1/4885PARG 4726/4885METAP2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.